9 different filers disclosed LLY within 90 days. Disclosed 9 days after the transaction; reported as an official range, not an exact amount.
Traded Nov 21, 2025 · Filed Nov 24, 2025
A big owner of Eli Lilly sold $8.04M of Eli Lilly shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$8,040,946
Shares × reported transaction price
22 days after results of Oct 30, 2025, 75 days before results of Feb 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $1,059.70 on Nov 21, 2025, at its 52-week high, after a 27% rise over the previous 30 trading days
52-week range $625.65 (Aug 8, 2025) to $1,059.70 (Nov 21, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $833.49 on Oct 10, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Retevmo on Nov 20, 2025, 1 day before this trade.
New use approved (efficacy supplement). Active ingredient: Selpercatinib. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -5.8% | +1.0% | -6.7% |
| 30 days | -2.9% | +2.3% | -5.2% |
| 90 days | -4.6% | +1.1% | -5.7% |
| 180 days | -4.1% | +11.2% | -15.3% |
Past results only. Not a forecast.
9 different filers disclosed LLY within 90 days. Disclosed 9 days after the transaction; reported as an official range, not an exact amount.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.